Cutaneous T-Cell Lymphoma
Study data from University of Texas provide new insights into cutaneous t-cell lymphoma
Published in Drug Law Weekly, January 19th, 2010
"Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies. A multicenter, open-label phase IIb trial evaluated the activity and safety of vorinostat 400 mg orally daily in patients with >= stage IB, persistent, progressive, or treatment-refractory mycosis fungoides or Sezary syndrome CTCL subtypes," scientists writing in the journal Clinical Lymphoma & Myeloma report.
"We report the safety and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2010-01-19)
More Articles from Drug Law Weekly
- Adventrx Pharmaceuticals, Inc.
ADVENTRX Pharmaceuticals Announces Closing of Financing - Anemia
Study results from University of California provide new insights into anemia - Bartell Drugs
Bartell Drugs Cites Reduced Compensation by the State of Washington; Discontinues Filling DSHS/Medicaid Prescriptions at 15 Locations - Behavioral Innovations
First Autism Treatment Center in Dallas to Provide Insurance Relief for Parents - Biopharmaceuticals
Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Effic - Boomerang Systems, Inc.
Boomerang Systems, Inc. Elects Steven C. Rockefeller, Jr. to the Board of Directors - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
